Compliance & Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.
Editorial policy
Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.
Oral vs Injectable NAD+: Administration Routes
NAD+ is supplemented via two primary routes: oral precursors (NMN/NR tablets/capsules) and intravenous NAD+ (pharmaceutical-grade). Oral precursors are non-invasive, convenient, and cost-effective ($40-80/month). IV NAD+ is expensive ($200-500/session), requires medical supervision, and is not FDA-approved but available through private clinics.
Most users prefer oral precursors for long-term supplementation. IV NAD+ is used by some for acute energy restoration or advanced protocols, but oral precursors provide sustained tissue benefit with less cost and risk.
Oral NAD+ Precursor Administration
NMN and NR are taken orally as capsules or tablets. Dosing: 250-1,000 mg daily, typically with breakfast for optimal absorption. Tablets should be swallowed whole with water. Some brands offer sublingual (under-tongue) formulations for faster absorption, though bioavailability differences are minimal.
Take with food to minimize nausea. Consistent daily timing (breakfast) maintains diurnal NAD+ rhythm and sustained energy. No special administration technique needed—standard oral supplementation.
Intravenous NAD+ Administration
IV NAD+ is pharmaceutical-grade NAD+ administered directly into bloodstream via IV infusion. Dosing: 250-500 mg per session, administered over 15-30 minutes. IV clinics recommend 1-2 sessions weekly for sustained benefit, though dosing varies by clinic protocol.
IV NAD+ bypasses oral absorption barriers, achieving 100% bioavailability and rapid peak NAD+ elevation. However, IV NAD+ rapidly clears from blood (20-40 minute half-life), requiring frequent infusions to maintain elevated tissue NAD+. Oral precursors may produce more sustained tissue elevation with daily dosing.
Intramuscular vs Subcutaneous NAD+ Injections
Some clinics offer intramuscular (IM) or subcutaneous (SC) NAD+ injections as intermediate routes between oral and IV. IM/SC NAD+ provides faster absorption than oral with less cost than IV. Dosing varies by clinic; typical protocols are 100-250 mg 1-3x weekly.
Efficacy compared to oral precursors and IV NAD+ is understudied. Most data supports oral precursors for cost-effectiveness and IV NAD+ for acute benefits. IM/SC injections are increasingly popular in integrative medicine clinics but lack robust clinical evidence.
Sublingual NAD+ Administration
Some brands offer sublingual NAD+ or sublingual precursor formulations that dissolve under the tongue. Sublingual administration may bypass first-pass liver metabolism, theoretically improving bioavailability. However, clinical data show minimal bioavailability advantage over standard oral capsules.
Sublingual formulations may offer better absorption in individuals with impaired digestion or malabsorption. For most users, standard oral tablets are equally effective and more convenient.
Absorption Optimization for Oral NAD+ Precursors
Absorption is improved by: taking with fatty food (enhances absorption window), maintaining adequate stomach acid pH (avoid excessive antacids), avoiding high-dose B vitamins that compete for absorption. Taking NAD+ with breakfast containing healthy fat optimizes intestinal absorption and bioavailability.
Digestive health matters; individuals with low stomach acid, IBS, or malabsorption may benefit from IV or IM administration. Otherwise, standard oral dosing with breakfast achieves 40-60% bioavailability—sufficient for systemic NAD+ elevation.
Timing of NAD+ Administration
Take oral NAD+ with breakfast for sustained morning-to-evening elevation and to maintain circadian NAD+ rhythm. Some users employ split dosing (breakfast + lunch) for more stable intracellular levels, but single morning dosing is simpler and equally effective for most.
IV NAD+ timing is flexible; some clinics recommend infusions 1-2x weekly evenly spaced (Monday/Thursday). Frequency depends on user goals and clinic protocol. Athletic performance protocols may sync IV sessions with heavy training days.
Administration Side Effects and Tolerance
Oral NAD+ may cause transient nausea, especially on empty stomach or at high doses. Taking with food minimizes nausea significantly. IV NAD+ may cause flushing, arm vein pain, or transient headache during infusion. These are mild and typically resolve by end of session.
No serious adverse events reported from oral or IV NAD+ at therapeutic doses. Nausea is dose-dependent; reduce dose if experienced. IV pain is reduced by experienced clinicians using proper infusion technique and concentration.
Long-Term Administration Safety
Oral NAD+ precursors are safe for indefinite daily use. No organ toxicity or serious adverse effects documented in human trials up to 2 years. IV NAD+ long-term safety is less studied due to limited clinical use, but acute safety is excellent.
Medical supervision is recommended for IV NAD+ to monitor for rare complications (infection, thrombosis). Oral precursors require no medical oversight. Either route is suitable for long-term anti-aging supplementation when administered correctly.